Protalix BioTherapeutics, Inc. Common Stock (PLX) Stock
Key stats
- Market cap
- $263.92M
- Price / Earnings ratio
- 12.2x
- EPS (TTM)
- $0.24
- Volume
- Loading
- 52-week high
- $3.19
- 52-week low
- $1.65
Source: third-party data provider, as of November 13, 2026
Compare with PLX
Recent news

Protalix BioTherapeutics advances Fabry disease and gout programs during 2025
Protalix BioTherapeutics advances Fabry disease and gout programs during 2025
PLX

Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen
Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen
PLX

PLX Shares Jump 13% On EMA Committee’s Turnaround On New Dosing Regimen For Fabry Disease Therapy
PLX Shares Jump 13% On EMA Committee’s Turnaround On New Dosing Regimen For Fabry Disease Therapy
PLX

Protalix wins EU panel backing for expanded dosing of Fabry disease drug
Protalix wins EU panel backing for expanded dosing of Fabry disease drug
PLX
Technical indicators
- RSI 14
- 71.22
- MACD 12/26/9
- 0.04
- EMA 9 of MACD
- -0.01
- MACD histogram
- 0.05
- SMA 50
- $2.67
- Price above SMA 50
- EMA 50
- $2.63
- Price above EMA 50
- SMA 200
- $2.44
- Price above SMA 200
- EMA 200
- $2.41
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Protalix BioTherapeutics advances Fabry disease and gout programs during 2025
Protalix BioTherapeutics advances Fabry disease and gout programs during 2025
PLX

Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen
Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen
PLX

PLX Shares Jump 13% On EMA Committee’s Turnaround On New Dosing Regimen For Fabry Disease Therapy
PLX Shares Jump 13% On EMA Committee’s Turnaround On New Dosing Regimen For Fabry Disease Therapy
PLX

Protalix wins EU panel backing for expanded dosing of Fabry disease drug
Protalix wins EU panel backing for expanded dosing of Fabry disease drug
PLX

Protalix BioTherapeutics CEO outlines 2026 priorities, highlights progress across clinical pipeline
Protalix BioTherapeutics CEO outlines 2026 priorities, highlights progress across clinical pipeline
PLX

Protalix BioTherapeutics partners with Secarna Pharmaceuticals on rare kidney disease drug development
Protalix BioTherapeutics partners with Secarna Pharmaceuticals on rare kidney disease drug development
PLX

These Israeli pharmaceutical stocks are down in the wake of Hamas attack
These Israeli pharmaceutical stocks are down in the wake of Hamas attack
PLX

Best Penny Stocks To Buy Today? 4 To Watch Under $5
Best Penny Stocks To Buy Today? 4 To Watch Under $5
PLX

Penny Stocks To Buy Now: 7 To Watch Before Next Week
Penny Stocks To Buy Now: 7 To Watch Before Next Week
PLX
About Protalix BioTherapeutics, Inc. Common Stock
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Dror Bashan | President, CEO & Director | 1967 |
| Mr. Gilad Mamlok | Senior VP, CFO Treasurer & Secretary | 1968 |
| Mr. Yaron Naos B.Sc., MBA | SVP & COO | 1964 |
| Ms. Yael Fellous | Vice President of Human Resources | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 71.22
- MACD 12/26/9
- 0.04
- EMA 9 of MACD
- -0.01
- MACD histogram
- 0.05
- SMA 50
- $2.67
- Price above SMA 50
- EMA 50
- $2.63
- Price above EMA 50
- SMA 200
- $2.44
- Price above SMA 200
- EMA 200
- $2.41
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $12.00
- Average
- $12.00
- High
- $12.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -19.1 | -6.7 | ||||||||||
| 2022 | -7.7 | -4.5 | +26.2 | +10.5 | +4.4 | -9.2 | -2.8 | +4.7 | -4.6 | -1.9 | +5.8 | +24.5 |
| 2023 | +13.9 | +19.8 | +6.1 | +25.8 | -27.9 | -6.5 | -13.0 | +16.0 | -16.2 | +7.1 | -6.8 | +21.9 |
| 2024 | -20.3 | +10.9 | -22.2 | -8.8 | -6.6 | +1.7 | -7.7 | -11.3 | -4.7 | +11.4 | +37.6 | +12.6 |
| 2025 | +23.4 | -3.7 | +10.8 | +20.9 | -48.3 | -6.3 | -1.4 | +6.9 | +35.4 | +0.4 | -25.5 | +5.9 |
| 2026 | +34.5 | +10.8 | -28.4 | -1.8 | -0.5 | +13.1 | +3.0 | +10.8 | +6.6 | -3.4 | +22.3 |



